252 related articles for article (PubMed ID: 26537608)
1. The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease.
Penny MA; Pemberton-Ross P; Smith TA
Malar J; 2015 Nov; 14():437. PubMed ID: 26537608
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
[TBL] [Abstract][Full Text] [Related]
3. The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models.
Penny MA; Galactionova K; Tarantino M; Tanner M; Smith TA
BMC Med; 2015 Jul; 13():170. PubMed ID: 26219380
[TBL] [Abstract][Full Text] [Related]
4. Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa.
Leach A; Vekemans J; Lievens M; Ofori-Anyinam O; Cahill C; Owusu-Agyei S; Abdulla S; Macete E; Njuguna P; Savarese B; Loucq C; Ballou WR;
Malar J; 2011 Aug; 10():224. PubMed ID: 21816029
[TBL] [Abstract][Full Text] [Related]
5. Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study.
Regules JA; Cicatelli SB; Bennett JW; Paolino KM; Twomey PS; Moon JE; Kathcart AK; Hauns KD; Komisar JL; Qabar AN; Davidson SA; Dutta S; Griffith ME; Magee CD; Wojnarski M; Livezey JR; Kress AT; Waterman PE; Jongert E; Wille-Reece U; Volkmuth W; Emerling D; Robinson WH; Lievens M; Morelle D; Lee CK; Yassin-Rajkumar B; Weltzin R; Cohen J; Paris RM; Waters NC; Birkett AJ; Kaslow DC; Ballou WR; Ockenhouse CF; Vekemans J
J Infect Dis; 2016 Sep; 214(5):762-71. PubMed ID: 27296848
[TBL] [Abstract][Full Text] [Related]
6. The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination.
Vandoolaeghe P; Schuerman L
Expert Rev Vaccines; 2016 Dec; 15(12):1481-1493. PubMed ID: 27841689
[TBL] [Abstract][Full Text] [Related]
7. [The RTS,S/AS01 malaria vaccine in children aged 5-17 months at first vaccination].
Vandoolaeghe P; Schuerman L
Pan Afr Med J; 2018; 30():142. PubMed ID: 30374388
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial.
White MT; Verity R; Griffin JT; Asante KP; Owusu-Agyei S; Greenwood B; Drakeley C; Gesase S; Lusingu J; Ansong D; Adjei S; Agbenyega T; Ogutu B; Otieno L; Otieno W; Agnandji ST; Lell B; Kremsner P; Hoffman I; Martinson F; Kamthunzu P; Tinto H; Valea I; Sorgho H; Oneko M; Otieno K; Hamel MJ; Salim N; Mtoro A; Abdulla S; Aide P; Sacarlal J; Aponte JJ; Njuguna P; Marsh K; Bejon P; Riley EM; Ghani AC
Lancet Infect Dis; 2015 Dec; 15(12):1450-8. PubMed ID: 26342424
[TBL] [Abstract][Full Text] [Related]
9. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial.
Aponte JJ; Aide P; Renom M; Mandomando I; Bassat Q; Sacarlal J; Manaca MN; Lafuente S; Barbosa A; Leach A; Lievens M; Vekemans J; Sigauque B; Dubois MC; Demoitié MA; Sillman M; Savarese B; McNeil JG; Macete E; Ballou WR; Cohen J; Alonso PL
Lancet; 2007 Nov; 370(9598):1543-51. PubMed ID: 17949807
[TBL] [Abstract][Full Text] [Related]
10. Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS,S/AS02 in Mozambique.
Campo JJ; Sacarlal J; Aponte JJ; Aide P; Nhabomba AJ; Dobaño C; Alonso PL
Vaccine; 2014 Apr; 32(19):2209-16. PubMed ID: 24631081
[TBL] [Abstract][Full Text] [Related]
11. Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial.
Tinto H; Otieno W; Gesase S; Sorgho H; Otieno L; Liheluka E; Valéa I; Sing'oei V; Malabeja A; Valia D; Wangwe A; Gvozdenovic E; Guerra Mendoza Y; Jongert E; Lievens M; Roman F; Schuerman L; Lusingu J
Lancet Infect Dis; 2019 Aug; 19(8):821-832. PubMed ID: 31300331
[TBL] [Abstract][Full Text] [Related]
12. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.
; Agnandji ST; Lell B; Fernandes JF; Abossolo BP; Methogo BG; Kabwende AL; Adegnika AA; Mordmüller B; Issifou S; Kremsner PG; Sacarlal J; Aide P; Lanaspa M; Aponte JJ; Machevo S; Acacio S; Bulo H; Sigauque B; Macete E; Alonso P; Abdulla S; Salim N; Minja R; Mpina M; Ahmed S; Ali AM; Mtoro AT; Hamad AS; Mutani P; Tanner M; Tinto H; D'Alessandro U; Sorgho H; Valea I; Bihoun B; Guiraud I; Kaboré B; Sombié O; Guiguemdé RT; Ouédraogo JB; Hamel MJ; Kariuki S; Oneko M; Odero C; Otieno K; Awino N; McMorrow M; Muturi-Kioi V; Laserson KF; Slutsker L; Otieno W; Otieno L; Otsyula N; Gondi S; Otieno A; Owira V; Oguk E; Odongo G; Woods JB; Ogutu B; Njuguna P; Chilengi R; Akoo P; Kerubo C; Maingi C; Lang T; Olotu A; Bejon P; Marsh K; Mwambingu G; Owusu-Agyei S; Asante KP; Osei-Kwakye K; Boahen O; Dosoo D; Asante I; Adjei G; Kwara E; Chandramohan D; Greenwood B; Lusingu J; Gesase S; Malabeja A; Abdul O; Mahende C; Liheluka E; Malle L; Lemnge M; Theander TG; Drakeley C; Ansong D; Agbenyega T; Adjei S; Boateng HO; Rettig T; Bawa J; Sylverken J; Sambian D; Sarfo A; Agyekum A; Martinson F; Hoffman I; Mvalo T; Kamthunzi P; Nkomo R; Tembo T; Tegha G; Tsidya M; Kilembe J; Chawinga C; Ballou WR; Cohen J; Guerra Y; Jongert E; Lapierre D; Leach A; Lievens M; Ofori-Anyinam O; Olivier A; Vekemans J; Carter T; Kaslow D; Leboulleux D; Loucq C; Radford A; Savarese B; Schellenberg D; Sillman M; Vansadia P
N Engl J Med; 2012 Dec; 367(24):2284-95. PubMed ID: 23136909
[TBL] [Abstract][Full Text] [Related]
13. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models.
Penny MA; Verity R; Bever CA; Sauboin C; Galactionova K; Flasche S; White MT; Wenger EA; Van de Velde N; Pemberton-Ross P; Griffin JT; Smith TA; Eckhoff PA; Muhib F; Jit M; Ghani AC
Lancet; 2016 Jan; 387(10016):367-375. PubMed ID: 26549466
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.
Bojang KA; Milligan PJ; Pinder M; Vigneron L; Alloueche A; Kester KE; Ballou WR; Conway DJ; Reece WH; Gothard P; Yamuah L; Delchambre M; Voss G; Greenwood BM; Hill A; McAdam KP; Tornieporth N; Cohen JD; Doherty T;
Lancet; 2001 Dec; 358(9297):1927-34. PubMed ID: 11747915
[TBL] [Abstract][Full Text] [Related]
15. RTS,S: Toward a first landmark on the Malaria Vaccine Technology Roadmap.
Kaslow DC; Biernaux S
Vaccine; 2015 Dec; 33(52):7425-32. PubMed ID: 26431982
[TBL] [Abstract][Full Text] [Related]
16. The biological function of antibodies induced by the RTS,S/AS01 malaria vaccine candidate is determined by their fine specificity.
Chaudhury S; Ockenhouse CF; Regules JA; Dutta S; Wallqvist A; Jongert E; Waters NC; Lemiale F; Bergmann-Leitner E
Malar J; 2016 May; 15():301. PubMed ID: 27245446
[TBL] [Abstract][Full Text] [Related]
17. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research.
Kester KE; Cummings JF; Ockenhouse CF; Nielsen R; Hall BT; Gordon DM; Schwenk RJ; Krzych U; Holland CA; Richmond G; Dowler MG; Williams J; Wirtz RA; Tornieporth N; Vigneron L; Delchambre M; Demoitie MA; Ballou WR; Cohen J; Heppner DG;
Vaccine; 2008 Apr; 26(18):2191-202. PubMed ID: 18387719
[TBL] [Abstract][Full Text] [Related]
18. Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa.
Guerra Mendoza Y; Garric E; Leach A; Lievens M; Ofori-Anyinam O; Pirçon JY; Stegmann JU; Vandoolaeghe P; Otieno L; Otieno W; Owusu-Agyei S; Sacarlal J; Masoud NS; Sorgho H; Tanner M; Tinto H; Valea I; Mtoro AT; Njuguna P; Oneko M; Otieno GA; Otieno K; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kremsner P; Lanaspa M; Lell B; Lusingu J; Malabeja A; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Adjei S; Agbenyega T; Agnandji ST; Schuerman L
Hum Vaccin Immunother; 2019; 15(10):2386-2398. PubMed ID: 31012786
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa.
Otieno L; Guerra Mendoza Y; Adjei S; Agbenyega T; Agnandji ST; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kariuki S; Kremsner P; Lanaspa M; Lell B; Lievens M; Lusingu J; Malabeja A; Masoud NS; Mtoro AT; Njuguna P; Ofori-Anyinam O; Otieno GA; Otieno W; Owusu-Agyei S; Schuerman L; Sorgho H; Tanner M; Tinto H; Valea I; Vandoolaeghe P; Sacarlal J; Oneko M
Vaccine; 2020 Jan; 38(4):897-906. PubMed ID: 31708182
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial.
Alonso PL; Sacarlal J; Aponte JJ; Leach A; Macete E; Milman J; Mandomando I; Spiessens B; Guinovart C; Espasa M; Bassat Q; Aide P; Ofori-Anyinam O; Navia MM; Corachan S; Ceuppens M; Dubois MC; Demoitié MA; Dubovsky F; Menéndez C; Tornieporth N; Ballou WR; Thompson R; Cohen J
Lancet; 2004 Oct 16-22; 364(9443):1411-20. PubMed ID: 15488216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
